CRISPR Therapeutics Plans Cell Therapy Facility in Framingham, Massachusetts
06/29/2020
“We look forward to building a state-of-the-art manufacturing facility, which will accelerate our programs and allow us to scale for commercial supply. We are thankful for the support from the City of Framingham and the Commonwealth of Massachusetts, and we look forward to bringing our facility online rapidly,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “In addition to building out this internal manufacturing capacity, we will continue to work closely with our key manufacturing partners globally."
As the facility becomes fully operational, the Company expects to hire up to approximately 100 full-time employees. The new facility is being designed to provide GMP manufacturing according to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations and guidelines to support clinical supply and commercial product upon potential regulatory approval.
The company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom.
Most Read
-
-
Hitting the Reset Button: How to Pivot the Perception of Economic Development
Q2 2020
-
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Q4 2019
-
Finding Talent in a Time of Economic Change
Q2 2020
-
COVID-19 and Site Selection in the Near and Long Term
Q2 2020
-
Innovation in America Reaches New Heights
Q2 2020
-
What Does the Future Hold for FDI from Europe?
Q3 2020